AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Growth-Factor-Based Vaccine Abrogates Angiogenesis and Tumor Formation.(Brief Article)

Vaccine Weekly

| February 21, 2001 | COPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2001 FEB 21 - (NewsRx.com & NewsRx.net) --

by Michelle Marble, staff medical writer -- Researchers in the United States hope that one day a simple vaccine may help treat certain cancers.

"Basic fibroblast growth factor (FGF-2) is an important stimulator of angiogenesis that has been implicated in neoplastic progression," wrote S.M. Plum and colleagues of EntreMed Inc., Rockville, Maryland. "Attempts to neutralize or modulate FGF-2 have met with some success in controlling neovascularity and tumor growth."

"In the present study, two peptides, one corresponding to the heparin binding domain and the other to the receptor binding domain of FGF-2, exerted dose-dependent inhibition of FGF-2-stimulated human umbilical vein endothelial cell proliferation (IC[50]=70 and 20 (micro)g/ml, respectively)," the researchers said. "The identification of these functional regions suggested that targeting these domains might be an approach for the modulation of FGF-2 function."

Both peptides were in a liposome/adjuvant format. Mice were vaccinated with one or the other. The researchers then analyzed the effect of the vaccines on FGF-2-driven angiogenesis, tumor development, and immune status in two tumor models: the B16BL6 melanoma and the Lewis lung carcinoma.

According to the authors, the mice vaccinated with the heparin binding domain peptide generated a specific antibody response to FGF-2. These mice blocked ...

Related articles from newspapers, magazines, journals, and more
Competitor Analysis: FGF-R Agonists and Antagonist - A Compilation of Current...
Press release article from: M2 Presswire November 5, 2009 700+ words
...Research and Markets: Competitor Analysis: FGF-R Agonists and Antagonist - A Compilation...Research and Development of Molecules Targeting FGF(C)1994-2009 M2 COMMUNICATIONS RDATE...addition of the "Competitor Analysis: FGF-R Agonists and Antagonists" report to...
"Naan" too soon.(FGF Inc wins Spirit of Innovation Award for Fabulous...
Magazine article from: Prepared Foods Roberts, William A., Jr. October 1, 2006 700+ words
...in the 2005 Spirit of Innovation Awards, FGF Brands returned in 2006, determined to...the increasingly diverse American palate, FGF depended upon strong, knowledgeable teams...2006 Spirit of Innovation Award- Retail. FGF Brands' stated product goal would seem...
Research and Markets: Competitor Analysis: FGF-R Agonists and Antagonist - A...
Press release article from: Business Wire November 5, 2009 700+ words
...addition of the "Competitor Analysis: FGF-R Agonists and Antagonists" report to...present Competitive Intelligence Report about FGF-R agonists and antagonists provides a...field of fibroblast growth factor receptor (FGF-R) or PDGF targeting molecules for wound...
SCIOS LICENSES FGF TO CHIRON IN $24.5M ANGIOGENIC ALLIANCE.
Magazine article from: BIOWORLD Today Pihl-Carey, Karen November 3, 1999 700+ words
...its human basic fibroblast growthfactor (FGF) to Chiron Corp. in a $24.5 millionagreement...based Chiron receives exclusiverights to FGF in all countries where it is not alreadypartnered...royalties based on salesof human or bovine FGF products. No further detailswere disclosed...
Chiron Announces Results of FGF-2 Phase II Clinical Trial in Peripheral Artery...
Press release article from: PR Newswire January 27, 2001 700+ words
...recombinant fibroblast growth factor-2 protein (FGF-2) in peripheral artery disease (PAD...peak walking time between the single-dose FGF treatment group and placebo (ANOVA, p...predefined secondary analysis. "Chiron's FGF-2 trials are one of the first robust trials...
Chiron and Scios Announce $25 Million Licensing Agreement on FGF.
Press release article from: PR Newswire November 2, 1999 700+ words
...in human basic fibroblast growth factor (FGF). Chiron will pay Scios $12.5 million...will receive royalties based on sales of FGF products (human or bovine) in countries...peripheral vascular disease -- using bovine FGF." "We are pleased to have licensed rights...
Denatured collagen used as support for FGF-2 delivery system.
Newspaper article from: Health & Medicine Week June 14, 2004 700+ words
...Denatured collagen used as a support for an FGF-2 delivery system. "Collagen-based...significant hydrophilicity and a pH sensitivity. FGF-2 was mixed with either regular gelatin...homogenous distribution of radiolabeled FGF-2 within the sponge," continued Cote...
Evolutionary implications of FGF and distal-less expressions during...
Magazine article from: The Biological Bulletin Bates, William R. June 1, 1998 700+ words
...Members of the fibroblast growth factor (FGF) family of proteins have multiple functions...endogenous growth factor belonging to the FGF superfamily has been detected in a urochordate...results of a previous experiment suggest that FGF may play a role earlier in ascidian development...
For more facts and information, see all results

Source: HighBeam Research, Growth-Factor-Based Vaccine Abrogates Angiogenesis and Tumor...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA